Chai-3 Model Adopted by BMS and Pharma Giants for Drug Discovery
saranormous · x · 2026-08-20
- Partnership: Chai Discovery announced BMS will use its models to support new therapeutics discovery. Previous partners include Eli Lilly, Novartis, Pfizer, and argenx.
- Model Capabilities: Since rolling out Chai-3 earlier this year, leading biopharma companies have adopted the models. The company states that the latest model generations are critical in distinguishing successful molecule discovery.
- Industry View: Chai Discovery emphasizes that scientific discovery is the domain where access to frontier AI matters most, with their models playing a substantial role in the process.
More from Companies & People
- IR Expert Moves from LightOn to Perplexity AI — eliebakouch · 2026-08-20
- ARDD 2026 Agenda: Top AI, Pharma, and Policy Makers to Meet at Harvard — MaxUnfried · 2026-08-20
- Chinese AI Labs' Tolerance of Lower Profit is Under-explored — kevinsxu · 2026-08-20
- Chinese AI Models Lead Hugging Face Downloads; Adopted by Airbnb, DoorDash, Coinbase — pstAsiatech · 2026-08-20
- High School AI Elective: Curriculum Design and Community Feedback — SurfsUp704 · 2026-08-20
- Absolute Number of Low-Level Coders Growing: Depth Follows Simplified Entry — timigod · 2026-08-20